Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cetuximab plus simplified LV5FU2 and hepatic intra-arterial oxaliplatin for unresectable colorectal liver metastases
2006-001067-39Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Mar 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC), sponsored by Gustave Roussy. Primary endpoint: Objective response rate. Started Mar 2009; status: terminated.
02
Drugs
cetuximaboxaliplatinfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-001067-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001067-39.